Waters Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results

• Sales of $520 million declined 13% as reported and 12% in constant currency
• GAAP EPS of $1.98; non-GAAP EPS of $2.10, a 2% decrease from prior year
• Cost savings plan of $100 million on track for the year
• Strong free cash flow of $175 million for the quarter
• Share repurchases to remain suspended during the third quarter

MILFORD, Mass.--(BUSINESS WIRE)-- Waters Corporation (NYSE: WAT) today announced second quarter 2020 sales of $520 million, a 13% decrease as reported, compared to sales of $599 million for the second quarter of 2019. Foreign currency translation negatively impacted sales growth by approximately 1% for the quarter. The Company’s results were impacted by lower demand across all major geographies due to the COVID-19 pandemic.

On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2020 decreased to $1.98, compared to $2.08 for the second quarter of 2019. On a non-GAAP basis, EPS decreased to $2.10, compared to $2.14 in the second quarter of 2019. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website at http://www.waters.com under the caption “Investors.”

On a GAAP basis, net cash provided by operating activities was $199 million for the second quarter of 2020, compared to $127 million for the second quarter of 2019. On a non-GAAP basis, adjusted free cash flow for the second quarter of 2020 was $175 million versus $136 million for the second quarter of 2019.

For the first half of 2020, the Company’s sales were $985 million, a decrease of 12% as reported, compared to sales of $1,113 million for the first half of 2019. Foreign currency translation negatively impacted sales growth by approximately 1% for the first half of 2020.

On a GAAP basis, EPS for the first half of 2020 decreased to $2.83, compared to $3.57 for the first half of 2019. On a non-GAAP basis, EPS decreased to $3.25, compared to $3.73 in the first half of 2019.

On a GAAP basis, net cash provided by operating activities was $350 million for the first half of 2020, compared to $303 million for the first half of 2019. On a non-GAAP basis, adjusted free cash flow for the first half of 2020 was $296 million versus $294 million for the first half of 2019.

“As anticipated, our second quarter revenue declined due to the ongoing impacts of the COVID-19 pandemic. However, our results reflected modestly better-than-anticipated market conditions and strong execution by our global sales, service and operations teams," commented Chris O’Connell, President and Chief Executive Officer of Waters Corporation. “This revenue performance, combined with the benefits of our cost containment initiatives, drove solid margin and earnings results during the quarter. While risks and uncertainties remain in our operating environment, we are well-positioned to leverage our strong new product pipeline and are investing to take advantage of growth opportunities as demand normalizes.”

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant-currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant-currency growth rates in the tables below.

During the second quarter of 2020, sales into the pharmaceutical market declined 11% as reported and 10% in constant currency, sales into the industrial market declined 14% as reported and 13% in constant currency and sales into the academic and governmental markets declined 22% as reported and 21% in constant currency. For the first half of 2020, sales into the pharmaceutical market declined 9% as reported and 8% in constant currency, sales into the industrial market declined 11% as reported and 10% in constant currency and sales into the academic and governmental markets declined 23% as reported and 22% in constant currency.

During the second quarter, recurring revenues, which represent the combination of service and precision chemistries revenues, declined 4% as reported and 3% in constant currency, while instrument system sales declined 23% as reported and in constant currency. For the first half of 2020, recurring revenues declined 3% as reported and 2% in constant currency, while instrument system sales declined 22% as reported and 21% in constant currency.

Geographically, sales in Asia during the quarter declined 13% as reported and 12% in constant currency, sales in the Americas declined 15% (with U.S. sales declining 14%) and sales in Europe declined 11% as reported and 9% in constant currency. For the first half of 2020, sales in Asia declined 16% as reported and 15% in constant currency, sales in the Americas declined 11% (with U.S. sales declining 9%) and sales in Europe declined 5% as reported and 3% in constant currency.

Conference Call

Waters Corporation will webcast its second quarter 2020 financial results conference call today, July 28, 2020 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose “Investors” and click on the “Live Webcast.” A replay will be available through August 4, 2020 at midnight Eastern Time on the same website by webcast and also by phone at 800-395-6236.

About Waters Corporation

Waters Corporation (NYSE: WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With more than 7,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant-currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Waters Corporation’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Waters Corporation’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to the effects of the COVID-19 pandemic on our business, financial condition, results of operations and prospects, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or other reasons related to the pandemic, increased risks of cyber attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain, volatility and uncertainty in global capital markets limiting our ability to access capital, customers being unable to make timely payments for purchases and volatility in demand for our products; foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors or geographies from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom exiting the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2019, as well as in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” of the Company’s quarterly report on Form 10-Q for the quarterly period ended June 27, 2020, each as filed with the Securities and Exchange Commission (“SEC”), which discussions are incorporated by reference in this release, as updated by the Company’s future filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005139/en/